PTC Therapeutics
PTCT
202 hedge funds and large institutions have $3.81B invested in PTC Therapeutics in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 79 increasing their positions, 73 reducing their positions, and 27 closing their positions.
57% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $10.1M
30% more capital invested
Capital invested by funds: $2.94B → $3.81B (+$867M)
8% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 73
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
0% more funds holding
Funds holding: 202 → 202 (0)
0.62% less ownership
Funds ownership: 106.96% → 106.33% (-0.62%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$84.4M |
| 2 |
RI
RTW Investments
New York
|
+$67.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$53.4M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$23.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$54.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$24.4M |
| 3 |
AC
Armistice Capital
New York
|
-$21.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$19.8M |
| 5 |
BlackRock
New York
|
-$14.4M |
PTCT Hedge Fund Activity: Q1 2023 in Review
202 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2023, worth a combined $3.81B — up 30% from $2.94B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PTCT positions and 27 closed out — a net gain of 2 holders — while 79 added to existing stakes and 73 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $84.4M. The largest seller was Fidelity Investments, cutting an estimated $54.8M.
- 202 institutional investors held PTC Therapeutics (PTCT) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $3.81B of PTC Therapeutics stock for Q1 2023, up 30% quarter-over-quarter.
- 29 funds opened new PTC Therapeutics positions in Q1 2023 and 27 closed out, a net change of +2 holders.
- The largest PTC Therapeutics buyer in Q1 2023 was Adage Capital Partners, an estimated $84.4M added.
- The largest PTC Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $54.8M sold.
Based on aggregated 13F filings for Q1 2023.